The value of laboratory tests and ultrasonography in evaluating ovarian response to ovulation induction treatment with low-dose recombinant follicle-stimulating hormone

Basit Öğe Kaydı
dc.contributor.authorÖzkaya, O.
dc.contributor.authorKaya, H.
dc.contributor.authorSezik, M.
dc.contributor.authorAkyürek, Cemalettin
dc.contributor.authorÖzbaşar, D.
dc.date.accessioned2020-03-26T16:55:36Z
dc.date.available2020-03-26T16:55:36Z
dc.date.issued2004
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractObjective-To compare basal (cycle day 3) follicle-stimulating hormone (FSH) level, clomiphene citrate challenge test (CCCT), gonadotropin-releasing hormone agonist stimulation test (GAST), and mean ovarian volume estimation by ultrasound for predicting the subsequent ovarian response. Design-Prospective, randomized, clinical study. Setting-Referral university hospital. Patients-One hundred and forty-four women with unexplained infertility undergoing their first ovulation induction treatment with low-dose recombinant FSH. Interventions-Patients were randomized into four groups. Basal FSH levels were evaluated in group I (n = 36). Clomiphene citrate challenge test (CCCT) and gonadotropin-releasing hormone agonist stimulation test (GAST) were carried out in group II (n = 36) and group III (n = 36), respectively. Transvaginal ultrasound was performed for ovarian volume measurements in group IV (n = 36). In the subsequent cycle, all women received ovulation induction therapy with recombinant FSH. Main Outcome Measures-Number of mature (greater than or equal to 14 mm) follicles and the number of recombinant FSH ampules required for successful ovulation induction. Results-Ovarian volume estimation by transvaginal ultrasound, compared to the other three tests, had the most powerful positive correlation with the number of mature follicles (r = 0.84, P < .0001) and the most powerful negative correlation (r = -0.75, P < .0001) with the amount of recombinant FSH used per cycle. Conclusion-Mean ovarian volume estimation by transvaginal ultrasound might be more useful than basal FSH values, CCCT, and GAST for predicting ovarian response to low-dose recombinant FSH treatment.en_US
dc.identifier.endpage87en_US
dc.identifier.issn1534-892Xen_US
dc.identifier.issn1938-3622en_US
dc.identifier.issue2en_US
dc.identifier.pmid15188834en_US
dc.identifier.startpage83en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12395/19261
dc.identifier.volume49en_US
dc.identifier.wosWOS:000221743200005en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherMEDICAL SCIENCE PUBL INT, INCen_US
dc.relation.ispartofINTERNATIONAL JOURNAL OF FERTILITY AND WOMENS MEDICINEen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectovarian reserveen_US
dc.subjectovarian responseen_US
dc.subjectovarian volumeen_US
dc.subjectFSHen_US
dc.subjectclomiphene citrate challenge testen_US
dc.subjectgonadotropin-releasing hormone agonist stimulation testen_US
dc.titleThe value of laboratory tests and ultrasonography in evaluating ovarian response to ovulation induction treatment with low-dose recombinant follicle-stimulating hormoneen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu